Gilead Sciences Inc. said on April 12 that the company decided to stop a late-stage trial of the intravenous treatment Veklury in high-risk non-hospitalized patients with Covid-19.
A USA Today report found that from January through May 2020, 28 generic drugs in 405 dosages made the U.S. Food and Drug Administration’s list of drugs in shortage.